PL1682523T3 - Pochodne morfoliny jako inhibitory wychwytu zwrotnego noradrenaliny - Google Patents

Pochodne morfoliny jako inhibitory wychwytu zwrotnego noradrenaliny

Info

Publication number: PL1682523T3
Authority: PL; Poland
Prior art keywords: reuptake inhibitors; norepinephrine reuptake; morpholine derivatives; morpholine; derivatives
Prior art date: 2003-11-10

Application number

PL04794209T

Other languages

English (en)

Inventor

Gordon Iain Campbell

Manuel J Cases-Thomas

Teresa Man

John Joseph Masters

Hélene C E Rudyk

Magnus Wilhelm Walter

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-10

Filing date

2004-10-28

Publication date

2011-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29726235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1682523(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-10-28 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2011-01-31 Publication of PL1682523T3 publication Critical patent/PL1682523T3/pl

Links

150000002780 morpholines Chemical class 0.000 title 1
239000002767 noradrenalin uptake inhibitor Substances 0.000 title 1
229940127221 norepinephrine reuptake inhibitor Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Dermatology (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)

PL04794209T 2003-11-10 2004-10-28 Pochodne morfoliny jako inhibitory wychwytu zwrotnego noradrenaliny PL1682523T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB0326148.4A GB0326148D0 (en)	2003-11-10	2003-11-10	Morpholine derivatives
US53545904P	2004-01-09	2004-01-09
EP04794209A EP1682523B1 (en)	2003-11-10	2004-10-28	Morpholine derivatives as norepinephrine reuptake inhibitors
PCT/US2004/032771 WO2005047272A1 (en)	2003-11-10	2004-10-28	Morpholine derivatives as norepinephrine reuptake inhibitors

Publications (1)

Publication Number	Publication Date
PL1682523T3 true PL1682523T3 (pl)	2011-01-31

Family

ID=29726235

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04794209T PL1682523T3 (pl)	2003-11-10	2004-10-28	Pochodne morfoliny jako inhibitory wychwytu zwrotnego noradrenaliny

Country Status (33)

Country	Link
US (1)	US7423037B2 (pl)
EP (2)	EP1682523B1 (pl)
JP (1)	JP4850068B2 (pl)
KR (1)	KR100783855B1 (pl)
CN (1)	CN1878762B (pl)
AR (1)	AR046927A1 (pl)
AT (1)	ATE478057T1 (pl)
AU (1)	AU2004289616B2 (pl)
BR (1)	BRPI0415273B8 (pl)
CA (1)	CA2544649C (pl)
CR (1)	CR8390A (pl)
CY (1)	CY1110796T1 (pl)
DE (1)	DE602004028750D1 (pl)
DK (1)	DK1682523T3 (pl)
EA (1)	EA009960B1 (pl)
EC (1)	ECSP066555A (pl)
ES (1)	ES2348872T3 (pl)
GB (1)	GB0326148D0 (pl)
HR (1)	HRP20100476T1 (pl)
IL (1)	IL175365A (pl)
MA (1)	MA28330A1 (pl)
MY (1)	MY141048A (pl)
NO (1)	NO336268B1 (pl)
NZ (1)	NZ546067A (pl)
PE (1)	PE20050491A1 (pl)
PL (1)	PL1682523T3 (pl)
PT (1)	PT1682523E (pl)
SI (1)	SI1682523T1 (pl)
SV (1)	SV2006001934A (pl)
TW (1)	TWI339658B (pl)
UA (1)	UA85198C2 (pl)
WO (1)	WO2005047272A1 (pl)
ZA (1)	ZA200603680B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1729754B1 (en) *	2003-12-12	2008-07-02	Eli Lilly And Company	Selective norepinephrine reuptake inhibitors for the treatment of hot flashes
US8580776B2 (en) *	2007-07-10	2013-11-12	The Board Of Trustees Of The University Of Illinois	Compositions and methods for treating neurodegenerating diseases
RU2613633C1 (ru) *	2016-03-09	2017-03-21	федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России)	Хлорид 4-[(1Е)-1-(6-хлор-4-оксо-4Н-хромен-3-ил)-4-метилпент-1-ен-3-ил]морфолин-4-ия, способ его получения и противотуберкулезная активность
GB201915753D0 (en) *	2019-10-30	2019-12-11	Univ Warwick	Alzheimer's disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2645640A (en)		1953-07-14		Phenthiazine derivatives
NL108827C (pl)	1956-04-09
GB895309A (en)	1959-11-18	1962-05-02	Res Lab Dr C Janssen Nv	Pyrrolidine and piperidine derivatives
US3141823A (en)	1962-09-04	1964-07-21	Res Lab Dr C Janssen N V	Method for producing analgesia
US3539573A (en)	1967-03-22	1970-11-10	Jean Schmutz	11-basic substituted dibenzodiazepines and dibenzothiazepines
JPS54130587A (en)	1978-03-30	1979-10-09	Otsuka Pharmaceut Co Ltd	Carbostyryl derivative
US4804663A (en)	1985-03-27	1989-02-14	Janssen Pharmaceutica N.V.	3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en)	1985-04-10	1993-09-08	Lundbeck & Co As H	Indole derivatives
GB8607684D0 (en)	1986-03-27	1986-04-30	Ici America Inc	Thiazepine compounds
US4831031A (en)	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en)	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
US5238945A (en)	1989-04-11	1993-08-24	H. Lundbeck A/S	Method of treating psychoses
GB8908085D0 (en)	1989-04-11	1989-05-24	Lundbeck & Co As H	New therapeutic use
US5229382A (en)	1990-04-25	1993-07-20	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
US5312925A (en)	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
EG23659A (en)	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine
AU9214498A (en)	1997-09-23	1999-04-12	Eli Lilly And Company	Treatment of attention-deficit/hyperactivity disorder
CA2318268A1 (en)	1998-01-21	1999-07-29	Glaxo Group Limited	Pharmaceutically active morpholinol
WO2001000214A1 (en) *	1999-06-30	2001-01-04	Merck & Co., Inc.	Src kinase inhibitor compounds
US6465458B1 (en)	1999-07-01	2002-10-15	Pharmacia & Upjohn Company	Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
GB0120461D0 (en)	2001-08-22	2001-10-17	Astrazeneca Ab	Novel compounds
GB0219687D0 (en)	2002-08-23	2002-10-02	Lilly Co Eli	Benzyl morpholine derivatives
JP2004277318A (ja) *	2003-03-14	2004-10-07	Dainippon Pharmaceut Co Ltd	１−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
FR2852954B1 (fr)	2003-03-28	2006-07-14	Aventis Pharma Sa	Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent

2003
- 2003-11-10 GB GBGB0326148.4A patent/GB0326148D0/en not_active Ceased
2004
- 2004-10-22 TW TW093132096A patent/TWI339658B/zh not_active IP Right Cessation
- 2004-10-28 SI SI200431540T patent/SI1682523T1/sl unknown
- 2004-10-28 UA UAA200604519A patent/UA85198C2/ru unknown
- 2004-10-28 DK DK04794209.9T patent/DK1682523T3/da active
- 2004-10-28 ES ES04794209T patent/ES2348872T3/es not_active Expired - Lifetime
- 2004-10-28 DE DE602004028750T patent/DE602004028750D1/de not_active Expired - Lifetime
- 2004-10-28 EA EA200600945A patent/EA009960B1/ru unknown
- 2004-10-28 WO PCT/US2004/032771 patent/WO2005047272A1/en not_active Ceased
- 2004-10-28 EP EP04794209A patent/EP1682523B1/en not_active Expired - Lifetime
- 2004-10-28 BR BRPI0415273A patent/BRPI0415273B8/pt not_active IP Right Cessation
- 2004-10-28 JP JP2006539492A patent/JP4850068B2/ja not_active Expired - Lifetime
- 2004-10-28 US US10/577,841 patent/US7423037B2/en not_active Expired - Lifetime
- 2004-10-28 KR KR1020067008999A patent/KR100783855B1/ko not_active Expired - Lifetime
- 2004-10-28 CA CA2544649A patent/CA2544649C/en not_active Expired - Lifetime
- 2004-10-28 HR HR20100476T patent/HRP20100476T1/hr unknown
- 2004-10-28 AT AT04794209T patent/ATE478057T1/de active
- 2004-10-28 CN CN2004800331155A patent/CN1878762B/zh not_active Expired - Lifetime
- 2004-10-28 EP EP10162865A patent/EP2223916A1/en not_active Withdrawn
- 2004-10-28 NZ NZ546067A patent/NZ546067A/en not_active IP Right Cessation
- 2004-10-28 PL PL04794209T patent/PL1682523T3/pl unknown
- 2004-10-28 AU AU2004289616A patent/AU2004289616B2/en not_active Expired
- 2004-10-28 PT PT04794209T patent/PT1682523E/pt unknown
- 2004-11-08 MY MYPI20044640A patent/MY141048A/en unknown
- 2004-11-09 AR ARP040104126A patent/AR046927A1/es active IP Right Grant
- 2004-11-09 PE PE2004001093A patent/PE20050491A1/es active IP Right Grant
- 2004-11-10 SV SV2004001934A patent/SV2006001934A/es unknown
2006
- 2006-05-01 IL IL175365A patent/IL175365A/en active IP Right Grant
- 2006-05-09 EC EC2006006555A patent/ECSP066555A/es unknown
- 2006-05-09 ZA ZA200603680A patent/ZA200603680B/en unknown
- 2006-05-10 CR CR8390A patent/CR8390A/es unknown
- 2006-06-02 MA MA29074A patent/MA28330A1/fr unknown
- 2006-06-12 NO NO20062700A patent/NO336268B1/no unknown
2010
- 2010-09-23 CY CY20101100858T patent/CY1110796T1/el unknown

Also Published As

Publication number	Publication date
AU2004289616A1 (en)	2005-05-26
BRPI0415273B1 (pt)	2019-04-30
IL175365A (en)	2011-02-28
PE20050491A1 (es)	2005-08-24
KR100783855B1 (ko)	2007-12-10
ECSP066555A (es)	2006-10-17
GB0326148D0 (en)	2003-12-17
CR8390A (es)	2007-12-07
TW200524885A (en)	2005-08-01
ATE478057T1 (de)	2010-09-15
HK1095135A1 (en)	2007-04-27
NZ546067A (en)	2009-04-30
MA28330A1 (fr)	2006-12-01
CA2544649A1 (en)	2005-05-26
BRPI0415273A (pt)	2006-12-19
ZA200603680B (en)	2007-07-25
AU2004289616B2 (en)	2010-08-05
CY1110796T1 (el)	2015-06-10
DE602004028750D1 (de)	2010-09-30
AR046927A1 (es)	2006-01-04
JP4850068B2 (ja)	2012-01-11
SV2006001934A (es)	2006-02-15
ES2348872T3 (es)	2010-12-16
BRPI0415273B8 (pt)	2021-05-25
DK1682523T3 (da)	2010-11-15
EA200600945A1 (ru)	2006-10-27
TWI339658B (en)	2011-04-01
KR20060086408A (ko)	2006-07-31
US20070083046A1 (en)	2007-04-12
CA2544649C (en)	2012-08-14
EA009960B1 (ru)	2008-04-28
NO336268B1 (no)	2015-07-06
CN1878762B (zh)	2010-10-27
UA85198C2 (ru)	2009-01-12
WO2005047272A1 (en)	2005-05-26
PT1682523E (pt)	2010-09-20
HRP20100476T1 (hr)	2010-10-31
MY141048A (en)	2010-02-25
EP1682523A1 (en)	2006-07-26
SI1682523T1 (sl)	2010-12-31
IL175365A0 (en)	2006-09-05
EP2223916A1 (en)	2010-09-01
JP2007510720A (ja)	2007-04-26
CN1878762A (zh)	2006-12-13
EP1682523B1 (en)	2010-08-18
US7423037B2 (en)	2008-09-09
NO20062700L (no)	2006-08-08

Publication	Publication Date	Title
HUS1400012I1 (hu)	2020-12-28	Szerotonin újrafelvételt gátló fenilpiperazin-származékok
AP2048A (en)	2009-09-24	Diazepinoindole derivatives as kinase inhibitors
ZA200702394B (en)	2008-11-26	Indozolone derivatives as 11b-HSD1 inhibitors
PL364580A1 (pl)	2004-12-13	Pochodne cyklopropyloindolu jako selektywne inhibitory zwrotnego wychwytu serotoniny
ZA200700181B (en)	2009-03-25	Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
ZA200804489B (en)	2009-08-26	1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as PTP-AS inhibitors
IL176554A0 (en)	2006-10-31	Thiophene derivatives as chk 1 inhibitors
IL173381A0 (en)	2006-06-11	2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
PT1635840E (pt)	2008-09-17	Tiofenopirimidinonas como inibidores da 17-beta-hidroxiesteróide desidrogenase
IL172132A0 (en)	2006-04-10	Thienopyridone derivatives as kinase inhibitors
AP2006003767A0 (en)	2006-10-31	Morpholine compounds
AP2005003467A0 (en)	2006-12-31	N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline reuptake inhibitors.
IL175106A0 (en)	2006-09-05	Novel keto-oxadiazole derivatives as cathepsin inhibitors
PL1675817T3 (pl)	2016-03-31	Pochodne aminoalkanoli
TWI339658B (en)	2011-04-01	Morpholine derivatives as norepinephrine reuptake inhibitors
IS8467A (is)	2006-05-15	2-(1H-indólýlsúlfanýl)-bensýl amín afleiður sem valvís serótónín endurupptöku hindri (SSRI)
GB0308460D0 (en)	2003-05-21	Morpholine dopamine agonists
GB0313606D0 (en)	2003-07-16	Morpholine dopamine agonists
ZA200605531B (en)	2007-12-27	Thiophene derivatives as CHK 1 inhibitors